Flamingo Pharmaceuticals

What Flamingo Pharmaceuticals does

Flamingo Pharmaceuticals Ltd. is a privately held Indian pharmaceutical manufacturer founded in 1985 by Mr. Ashwin Thacker, originally as Flamingo Impex Pvt. Ltd., and headquartered in Mumbai. The company develops, manufactures, and exports prescription and OTC therapies across a broad range of finished dosage forms — tablets, capsules, creams/ointments, injections, oral liquids, PFS, softgels, PFOS, and suppositories — with a portfolio exceeding 500 formulations. Its Taloja Solid Dosage facility, approved by UK-MHRA and EU-GMP since 2005, anchors manufacturing operations, supplemented by a dedicated Betalactam/Antibiotics block, an in-house R&D laboratory focused on novel formulations and drug delivery systems, and a UK regional headquarters supplying 50+ products into the UK market.

The company's revenue model rests on two pillars: (1) product exports of pharmaceutical formulations to international distributors across approximately 50 countries spanning Africa, Southeast Asia, Central America, the Caribbean, the Middle East, Europe, and the US; and (2) contract manufacturing services delivered from EU-GMP/UK-MHRA approved facilities, primarily to European clients with stated expansion into US regulated markets. Go-to-market is executed through an enterprise Business Development division engaging directly with pharmaceutical companies, alongside a network of regional distributors. Pricing is not publicly disclosed and is contract-based for both B2B product sales and manufacturing services. Regulatory certifications — UK-MHRA, EU-GMP, USFDA, WHO-GMP, TGA (Australia), and Peru — form the structural backbone that enables access to regulated and semi-regulated markets globally.

The firm is founder-led, with no disclosed external funding rounds, acquisitions, IPO activity, or institutional investors identified in the available materials. Strategic posture emphasizes regulatory compliance, geographic diversification, cost-competitive quality manufacturing, and selective partnerships with biotech firms, research institutions, and licensing counterparties to broaden the formulation pipeline and market reach.

Name

Flamingo Pharmaceuticals

Legal name

Flamingo Pharmaceuticals Ltd.

Website

https://flamingopharma.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Flamingo Pharmaceuticals is a privately held Indian pharmaceutical manufacturer, founded in 1985, that develops and exports over 500 prescription and OTC formulations across multiple dosage forms to distributors in approximately 50 countries and provides EU-GMP/UK-MHRA contract manufacturing services to European clients.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Generic pharmaceutical manufacturing
• Finished dosage forms
• Pharmaceutical contract manufacturing
• Pharmaceutical product exports
• Prescription and OTC medicines

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing Services: Provides contract manufacturing services from EU-GMP/UK-MHRA approved facilities primarily to European clients, with expansion into US and additional parts of Europe. Manufacturing fees charged for formulation production.
2. Product Exports: Exports over 500 formulations in various dosage forms to approximately 50 countries across Africa, South East Asia, Central America, and regulated markets. Revenue generated from product sales to international distributors and customers.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Flamingo Pharmaceuticals develops, manufactures, and exports over 500 finished pharmaceutical formulations in multiple dosage forms (tablets, capsules, creams/ointments, injections, oral liquids, PFS, softgels, suppositories, PFOS) from WHO-GMP, UK-MHRA, USFDA, and EU-GMP certified facilities. The company also provides contract manufacturing services to European and US pharmaceutical clients from its Taloja solid-dosage facility, complemented by in-house R&D capabilities for novel formulations and drug delivery systems.

Product overview

Flamingo Pharmaceuticals is a pharmaceutical company that operates as a single unified offering rather than a platform-plus-modules architecture. The company's core products include over 500 pharmaceutical formulations across various dosage forms (tablets, capsules, creams/ointments, injections, oral liquids, softgels, suppositories, PFS, and PFOS), supplemented by contract manufacturing services from EU-GMP approved facilities. The company also provides R&D laboratory services and business development services including strategic partnerships, licensing, and market expansion. Flamingo supplies more than 50 products into the UK market across multiple therapeutic areas, with manufacturing operations extending across Europe and into regulated markets such as the US.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceutical Formulations (Tablets, Capsules, Creams/Ointments, PFOS, Injections, Oral Liquid, PFS, Softgels, Suppositories) Flamingo manufactures and exports over 500 finished pharmaceutical formulations across multiple dosage forms including tablets, capsules, creams/ointments, PFOS, injections, oral liquids, PFS, softgels, and suppositories, supplying more than 50 products into the UK market across multiple therapeutic areas and channels. These are sold to international pharmaceutical distributors and healthcare providers in regulated and emerging markets.
• Pharmaceutical Contract Manufacturing Services Contract manufacturing services for finished dosage forms, primarily provided to European pharmaceutical clients from Flamingo's UK-MHRA/EU-GMP approved solid-dosage manufacturing facility in Taloja, with operations extending across Europe and penetrating into US regulated markets. Targeted at pharmaceutical companies seeking compliant, cost-efficient third-party production capacity.
• Research and Development Laboratory Services Pharmaceutical R&D laboratory services focused on novel formulations, drug delivery systems, formulation development, and clinical trial support, leveraging advanced analytical tools and computational models for precision and accelerated development. Services include innovation incubation, excellence-driven development, and collaborative ecosystem partnerships with biotech firms, research institutions, and healthcare organizations.

Quantifiable outcome

• UK-MHRA/EU-GMP approval achieved in 2005 enabling entry into regulated European markets

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Biotech FirmscoreStrategic or Co-development PartnerFlamingo actively seeks collaborations with biotech firms to catalyze groundbreaking advancements in pharmaceuticals. These partnerships focus on joint innovation and development of novel therapeutic solutions.
• Research InstitutionscoreStrategic or Co-development PartnerStrategic partnerships with academic and research institutions worldwide to foster interdisciplinary collaboration and advance pharmaceutical research and development.
• Healthcare OrganizationscoreStrategic or Co-development PartnerCollaborations with healthcare organizations to drive innovation and expand access to affordable healthcare solutions globally.
• Licensing PartnerscoreOEM/ Whitelabel/ Licensing PartnerFlamingo pursues licensing agreements and acquisitions to secure novel compounds, technologies, and intellectual property rights that complement their portfolio and strengthen market position.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Glenmark Pharmaceuticals: Indian pharma manufacturer with global footprint, multiple manufacturing facilities, and broad formulation portfolio. Comparable in business model focused on generics and emerging market presence.
• Cadila Healthcare (Zydus): Large Indian pharma group with global generics business, USFDA/EU-GMP approved facilities, and broad therapeutic coverage. Comparable in formulation manufacturing and international reach.
• Strides Pharma: Indian pharma company focused on regulated markets with multiple regulatory approvals, generic formulations, and emerging market distribution. Closely comparable in size and strategic positioning.
• Cipla: Major Indian generic pharma manufacturer with global presence across 80+ countries, strong emerging markets distribution, and multiple dosage form offerings. Comparable in product breadth and geographic reach.
• Ipca Laboratories: Indian pharmaceutical manufacturer with focus on generic formulations, multiple manufacturing facilities with regulatory approvals, and global exports. Comparable scale and product offerings.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with USFDA/EU-GMP approved facilities exporting across 150+ countries, including significant contract manufacturing operations. Highly comparable business model to Flamingo's generic formulations + CDMO approach.
• Lupin Pharmaceuticals: Indian generic pharma with strong regulatory approvals (USFDA, UK-MHRA), manufacturing across multiple dosage forms, and global distribution. Similar formulation-focused portfolio with regulated market exposure.
• Torrent Pharmaceuticals: Indian generic pharma manufacturer with international operations across 40+ countries and diverse dosage form portfolio. Similar manufacturing and distribution model.

Broad incumbents

• Recipharm: European-based CDMO with multiple GMP-approved facilities offering contract manufacturing services to pharma companies. Comparable to Flamingo's contract manufacturing services business in Europe.

Emerging players

• Althea Pharma (Ajinomoto Bio-Pharma): Contract development and manufacturing organization offering formulation services. Adjacent comparator for Flamingo's contract manufacturing and R&D services capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/flamingo-pharmaceuticals-ltd/mycompany

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flamingo Pharmaceuticals